Jieun Shin
Primary Care · Garden Grove, CANPI 1275035917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nestle Healthcare Nutrition Inc.$2K
- Aimmune Therapeutics, Inc.$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$993
- plus $4K from 25 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$11,36798%
- Education$1852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nestle Healthcare Nutrition Inc. | 63 | $1,552 |
| Aimmune Therapeutics, Inc. | 50 | $1,317 |
| AstraZeneca | 43 | $1,313 |
| Lilly USA, LLC | 40 | $1,290 |
| Novo Nordisk | 63 | $1,045 |
| AbbVie | 50 | $993 |
| Boehringer Ingelheim | 37 | $924 |
| Amgen | 19 | $481 |
| Astellas Pharma US Inc | 15 | $479 |
| Ironwood Pharmaceuticals, Inc | 10 | $333 |
| Abbott | 9 | $298 |
| Gilead | 3 | $211 |
| Bayer | 10 | $201 |
| Vivus LLC | 8 | $162 |
| Lundbeck LLC | 7 | $147 |
| Amarin Pharma, Inc. | 6 | $127 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| Scilex Pharmaceuticals Inc. | 5 | $94 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Pfizer | 3 | $63 |
| Johnson & Johnson | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Dexcom, Inc. | 2 | $43 |
| Fidia Pharma USA Inc. | 2 | $39 |
| Merck | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Biogen | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,558 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 115 | $237,508 |
| ProliaDenosumab | 110 | $183,965 |
| VascepaIcosapent Ethyl | 427 | $178,491 |
| JardianceEmpagliflozin | 243 | $170,274 |
| CreonLipase/Protease/Amylase | 99 | $122,492 |
| TradjentaLinagliptin | 188 | $110,619 |
| ZtlidoLidocaine | 141 | $100,108 |
| JanuviaSitagliptin Phosphate | 139 | $93,949 |
| FarxigaDapagliflozin Propanediol | 148 | $91,698 |
| LinzessLinaclotide | 102 | $58,159 |
| OzempicSemaglutide | 49 | $54,439 |
| RybelsusSemaglutide | 19 | $31,677 |
| XareltoRivaroxaban | 49 | $30,474 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $28,517 |
| Icosapent Ethyl | 98 | $22,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Spiriva Respimat | $924 | $293,293454 claims |
| Aimmune Therapeutics, Inc.Zenpep | $1,317 | $237,508115 claims |
| AbbVieCreon, Linzess, Restasis | $993 | $195,624220 claims |
| AmgenProlia | $481 | $183,965110 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,313 | $120,215194 claims |
| MerckJanuvia, Janumet | $38 | $107,468163 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $94 | $100,108141 claims |
| Novo NordiskOzempic, Rybelsus | $1,045 | $86,11668 claims |
| Johnson & JohnsonXarelto | $59 | $30,47449 claims |
| PfizerEliquis, Premarin | $63 | $19,83236 claims |
| Astellas Pharma US IncMyrbetriq | $479 | $12,54525 claims |
| BayerKerendia | $201 | $9,34915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Garden Grove
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.